| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activating mutations in the epidermal growth factor receptor gene in non-small cell lung cancer fixed tissue: Analysis and one center experience
|
Tomíšková, M.
|
|
2012
|
77 |
S1 |
p. S40-
1 p.
|
artikel
|
| 2 |
Adjuvant chemotherapy of non-small cell lung cancer—From multicentre trials to routine clinical practice
|
Kolek, Vítězslav
|
|
2012
|
77 |
S1 |
p. S7-
1 p.
|
artikel
|
| 3 |
Alveolar macrophages’ lipid content in pulmonary sarcoidosis and lung cancer
|
Žunić, Svetlana
|
|
2012
|
77 |
S1 |
p. S42-S43
2 p.
|
artikel
|
| 4 |
A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice
|
Kolek, Vítězslav
|
|
2012
|
77 |
S1 |
p. S33-
1 p.
|
artikel
|
| 5 |
A pilot study evaluating inflammatory biochemical parameters and oxidative stress in patients undergoing VATS and open lobectomy for early stage NSCLC
|
Silins, Ints
|
|
2012
|
77 |
S1 |
p. S37-
1 p.
|
artikel
|
| 6 |
Are there several kinds of palliative care?
|
Klastersky, Jean A.
|
|
2012
|
77 |
S1 |
p. S6-
1 p.
|
artikel
|
| 7 |
A retrospective study of lung cancer in young patients hospitalized and treated in our clinic during 2005–2010
|
Ustamujić, A.
|
|
2012
|
77 |
S1 |
p. S40-S41
2 p.
|
artikel
|
| 8 |
Author Index
|
|
|
2012
|
77 |
S1 |
p. S45-S46
2 p.
|
artikel
|
| 9 |
Autophagy execution protein beclin1 regulates radiation-induced osteopontin in human lung cancer cell
|
Chang, Seung-Hee
|
|
2012
|
77 |
S1 |
p. S29-
1 p.
|
artikel
|
| 10 |
Bimodality or trimodality treatment in locally advanced NSCLC
|
Wagner, Wolfgang
|
|
2012
|
77 |
S1 |
p. S18-
1 p.
|
artikel
|
| 11 |
Biomarkers in customized therapy
|
Filipits, Martin
|
|
2012
|
77 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 12 |
Cetuximab in advanced non-small-cell lung cancer (NSCLC)
|
Pirker, Robert
|
|
2012
|
77 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 13 |
Concurrent chemoradiotherapy in locally advanced non-small cell lung cancer—Prognostic factors and reasons for treatment failure in group of patients 1996–2008
|
Zemanová, Milada
|
|
2012
|
77 |
S1 |
p. S42-
1 p.
|
artikel
|
| 14 |
Contents
|
|
|
2012
|
77 |
S1 |
p. vii-
1 p.
|
artikel
|
| 15 |
CT screening for lung cancer
|
Nackaerts, Kristiaan
|
|
2012
|
77 |
S1 |
p. S11-
1 p.
|
artikel
|
| 16 |
Current lung cancer therapy: The role of thoracic surgery
|
Hoda, Mir Ali Reza
|
|
2012
|
77 |
S1 |
p. S4-
1 p.
|
artikel
|
| 17 |
Definition of a fluorescence in situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
|
Schmitz, Katja
|
|
2012
|
77 |
S1 |
p. S14-
1 p.
|
artikel
|
| 18 |
Development and performance evaluation of a CE-IVD for measuring SHOX2 DNA methylation in bronchial aspirates for the diagnosis of lung cancer
|
Dietrich, Dimo
|
|
2012
|
77 |
S1 |
p. S22-
1 p.
|
artikel
|
| 19 |
DNA methylation downregulates expression of several apoptosis-associated and tumor suppressor genes in non-small cell lung carcinoma cells
|
Křepela, E.
|
|
2012
|
77 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 20 |
Early supportive care for lung cancer patients
|
Ripamonti, Carla Ida
|
|
2012
|
77 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 21 |
EBUS–EUS, mediastinoscopy
|
Dooms, Christophe
|
|
2012
|
77 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 22 |
Editorial Board
|
|
|
2012
|
77 |
S1 |
p. v-
1 p.
|
artikel
|
| 23 |
Effector and regulator T lymphocytes in late stages of non small cell lung cancer and chronic obstructive pulmonary disease
|
Galffy, Gabriella
|
|
2012
|
77 |
S1 |
p. S22-
1 p.
|
artikel
|
| 24 |
EGFR mutations in patients with advanced NSCLC
|
Fiala, Ondrej
|
|
2012
|
77 |
S1 |
p. S30-
1 p.
|
artikel
|
| 25 |
EGFR mutations in squamous NSCLC – Prevalence and treatment results with EGFR tyrosine kinase inhibitors (TKIs) in patients from western Slovakia
|
Berzinec, P.
|
|
2012
|
77 |
S1 |
p. S21-
1 p.
|
artikel
|
| 26 |
Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)
|
Petruzelka, Lubos
|
|
2012
|
77 |
S1 |
p. S25-
1 p.
|
artikel
|
| 27 |
Erlotinib treatment results in patients with advanced non-small-cell lung cancer (NSCLC)—Influence of clinical predictors
|
Salajka, F.
|
|
2012
|
77 |
S1 |
p. S36-S37
2 p.
|
artikel
|
| 28 |
ETOP activity in the field of biomarkers and predictors
|
Stahel, R.A.
|
|
2012
|
77 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 29 |
Fatigue and cachexia
|
Lainscak, Mitja
|
|
2012
|
77 |
S1 |
p. S10-
1 p.
|
artikel
|
| 30 |
Febrile neutropenia: Paradigms and perspectives
|
Klastersky, Jean A.
|
|
2012
|
77 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 31 |
Five years of gefitinib in patient with lung adenocarcinoma
|
Kotlanová, Š.
|
|
2012
|
77 |
S1 |
p. S43-
1 p.
|
artikel
|
| 32 |
Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
|
Skřičková, Jana
|
|
2012
|
77 |
S1 |
p. S37-S38
2 p.
|
artikel
|
| 33 |
Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months
|
Grygárková, I.
|
|
2012
|
77 |
S1 |
p. S31-
1 p.
|
artikel
|
| 34 |
Immunotherapy
|
Vansteenkiste, J.
|
|
2012
|
77 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 35 |
Induction of cellular immune response against autologous tumor cells by vaccination with autologous tumor lysate-pulsed dendritic cells
|
Yasumoto, Kosei
|
|
2012
|
77 |
S1 |
p. S27-
1 p.
|
artikel
|
| 36 |
Influence of palliative radiotherapy on prognosis and quality of life for patients with stage IV non-small cell lung cancer
|
Cao, JianZhong
|
|
2012
|
77 |
S1 |
p. S28-
1 p.
|
artikel
|
| 37 |
Inhalation of lentivirus-small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice
|
Yu, Kyeong-Nam
|
|
2012
|
77 |
S1 |
p. S42-
1 p.
|
artikel
|
| 38 |
Introducing the new biomarker research approach into practice: Preliminary data from CXCL4 chemokine study in non-small cell lung cancer (NSCLC)
|
Spaks, Artjoms
|
|
2012
|
77 |
S1 |
p. S26-
1 p.
|
artikel
|
| 39 |
In vitro culturing of circulating tumor cells in lung cancer management
|
Kološtová, Katarína
|
|
2012
|
77 |
S1 |
p. S23-
1 p.
|
artikel
|
| 40 |
Long-term survival after lobectomy and pneumonectomy in patients with stage II non-small cell lung cancer (NSCLC)
|
Spaks, Artjoms
|
|
2012
|
77 |
S1 |
p. S39-
1 p.
|
artikel
|
| 41 |
Lung cancer and smoking
|
Kralikova, Eva
|
|
2012
|
77 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 42 |
Lung cancer diagnostic algorithm
|
Huber, Rudolf M.
|
|
2012
|
77 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 43 |
Lung cancer in never smokers
|
Ostoros, Gyula
|
|
2012
|
77 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 44 |
Lung cancer in women
|
Vavalà, Tiziana
|
|
2012
|
77 |
S1 |
p. S12-
1 p.
|
artikel
|
| 45 |
Lung cancer surgery for elderly patients
|
Matsuda, Eisuke
|
|
2012
|
77 |
S1 |
p. S36-
1 p.
|
artikel
|
| 46 |
LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
|
Schuler, Martin
|
|
2012
|
77 |
S1 |
p. S25-S26
2 p.
|
artikel
|
| 47 |
MicroRNAs as a new class of lung cancer biomarkers
|
Slaby, Ondrej
|
|
2012
|
77 |
S1 |
p. S16-
1 p.
|
artikel
|
| 48 |
Molecular diagnostic algorithms in the era of personalized medicine of NSCLC
|
Tímár, J.
|
|
2012
|
77 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 49 |
Moringa oleifera: Natural leaf extract with potential anti-cancerous effect on A549 lung cancer cells
|
Dany, M.
|
|
2012
|
77 |
S1 |
p. S22-
1 p.
|
artikel
|
| 50 |
New vision, new hope: Building momentum in NSCLC
|
|
|
2012
|
77 |
S1 |
p. S44-
1 p.
|
artikel
|
| 51 |
Options of genetic testing and methylation analysis of circulating free tumor DNA (tumor cell-free DNA) isolated from peripheral blood of NSCLC patients
|
Pešek, Miloš
|
|
2012
|
77 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 52 |
Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival
|
Kolek, V.
|
|
2012
|
77 |
S1 |
p. S34-
1 p.
|
artikel
|
| 53 |
Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival
|
Kolek, Vítězslav
|
|
2012
|
77 |
S1 |
p. S33-S34
2 p.
|
artikel
|
| 54 |
Organizing and Scientific Committees
|
|
|
2012
|
77 |
S1 |
p. vi-
1 p.
|
artikel
|
| 55 |
Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009
|
Janku, Filip
|
|
2012
|
77 |
S1 |
p. S27-
1 p.
|
artikel
|
| 56 |
Pain management
|
Lossignol, D.
|
|
2012
|
77 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 57 |
Palliative care for patients with advanced lung cancer
|
Koczywas, M.
|
|
2012
|
77 |
S1 |
p. S32-S33
2 p.
|
artikel
|
| 58 |
Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy
|
Smith, David A.
|
|
2012
|
77 |
S1 |
p. S39-
1 p.
|
artikel
|
| 59 |
Primary lung cancer and combined sparoganosis were suspected by multiple distant metastasis in PET–CT imaging of patient with colon cancer
|
Yoon, Yoo Sang
|
|
2012
|
77 |
S1 |
p. S41-S42
2 p.
|
artikel
|
| 60 |
Pro-gastrin-releasing peptide (ProGRP)—Sensitive marker and prognostic factor in patients with small cell lung cancer
|
Tomíšková, M.
|
|
2012
|
77 |
S1 |
p. S40-
1 p.
|
artikel
|
| 61 |
Prognostic effect of drug resistance of glutathione-S-transferase in non small lung cancer
|
Aziz, H.
|
|
2012
|
77 |
S1 |
p. S21-
1 p.
|
artikel
|
| 62 |
Prognostic significance of TIMP-1 in non-small cell lung cancer
|
Svatoň, Martin
|
|
2012
|
77 |
S1 |
p. S39-S40
2 p.
|
artikel
|
| 63 |
Proton therapy in the treatment of non small cell lung cancer
|
Nichols, Romaine Charles
|
|
2012
|
77 |
S1 |
p. S11-
1 p.
|
artikel
|
| 64 |
Pulmonary small cell carcinoma with heterotopic ossification—Unique case report and review of literature
|
Budimir, Bernard
|
|
2012
|
77 |
S1 |
p. S37-
1 p.
|
artikel
|
| 65 |
Radiotherapy and targeted drugs
|
Dziadziuszko, Rafal
|
|
2012
|
77 |
S1 |
p. S2-
1 p.
|
artikel
|
| 66 |
Recent advances of biomarker research in lung cancer with special reference to new targeted therapies: Status and future challenges
|
Hirsch, Fred R.
|
|
2012
|
77 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 67 |
Regulation of serpinB9 expression in non-small cell lung carcinoma
|
Roušalová, I.
|
|
2012
|
77 |
S1 |
p. S36-
1 p.
|
artikel
|
| 68 |
Relative intensity of TP53 mutation is associated with intratumor genetic heterogeneity and the prognosis of patients with early stage non-small cell lung cancers
|
Yoo, Seung Soo
|
|
2012
|
77 |
S1 |
p. S41-
1 p.
|
artikel
|
| 69 |
Retreatment with erlotinib in NSCLC harboring EGFR mutation—Case report
|
Fiala, Ondrej
|
|
2012
|
77 |
S1 |
p. S29-
1 p.
|
artikel
|
| 70 |
Retrospective analysis of pain management in an in-hospital setting in cancer patients
|
Lossignol, Dominique
|
|
2012
|
77 |
S1 |
p. S29-
1 p.
|
artikel
|
| 71 |
Ribonucleotide reductase subunit 2 (RRM2) predicts shorter survival in resected stage I–III non-small cell lung cancer (NSCLC) patients
|
Grossi, F.
|
|
2012
|
77 |
S1 |
p. S23-
1 p.
|
artikel
|
| 72 |
Sensitization of cancer cells to TRAIL-induced apoptosis by drugs targeting mitochondrial ROS and endoplasmic reticulum
|
Suzuki, Yoshihiro
|
|
2012
|
77 |
S1 |
p. S26-
1 p.
|
artikel
|
| 73 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice
|
Fiala, Ondrej
|
|
2012
|
77 |
S1 |
p. S30-
1 p.
|
artikel
|
| 74 |
Small-cell lung cancer
|
Postmus, Pieter E.
|
|
2012
|
77 |
S1 |
p. S19-S20
2 p.
|
artikel
|
| 75 |
Small cell lung cancer treatment in Paul Stradins Clinical University Hospital (Riga, Latvia) – Update after 3 year follow up
|
Kozirovskis, Viktors
|
|
2012
|
77 |
S1 |
p. S34-S35
2 p.
|
artikel
|
| 76 |
Specific needs in lung cancer patients
|
Skřičková, Jana
|
|
2012
|
77 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 77 |
Start of lymph node metastases of non-small cell lung cancer depended on cell ratio factors
|
Kshivets, O.
|
|
2012
|
77 |
S1 |
p. S35-
1 p.
|
artikel
|
| 78 |
Stereotactic body radiotherapy for early stage non-small cell lung cancer
|
Lagerwaard, F.
|
|
2012
|
77 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 79 |
Suppression of lung cancer cell growth in vitro and in vivo by Leucine zipper/EF hand-containing transmembrane-1
|
Lee, Kyung-A.
|
|
2012
|
77 |
S1 |
p. S35-
1 p.
|
artikel
|
| 80 |
Survivin expression in non small lung cancer tissues. Preliminary results of a centre. Our experience
|
Kapellos, G.
|
|
2012
|
77 |
S1 |
p. S32-
1 p.
|
artikel
|
| 81 |
Survivin levels in small and non small lung cancer patients. Is an important or conflicting predictive marker? Preliminary results of our centre
|
Kapellos, G.
|
|
2012
|
77 |
S1 |
p. S32-
1 p.
|
artikel
|
| 82 |
Targeted therapy of EGFR mutated lung adenocarcinoma as neoadjuvant treatment followed lung resection—Case report
|
Bednářová, V.
|
|
2012
|
77 |
S1 |
p. S28-
1 p.
|
artikel
|
| 83 |
Targeted therapy of metastatic NSCLC in clinical setting at US
|
Krizan, Zdenko
|
|
2012
|
77 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 84 |
Targeting the blood vasculature
|
Dome, Balazs
|
|
2012
|
77 |
S1 |
p. S1-
1 p.
|
artikel
|
| 85 |
The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)
|
Skřičková, Jana
|
|
2012
|
77 |
S1 |
p. S38-
1 p.
|
artikel
|
| 86 |
The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line
|
Grossi, F.
|
|
2012
|
77 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 87 |
The role of miRNA expressions in multidrug resistance in NSCLC
|
Skarda, Jozef
|
|
2012
|
77 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 88 |
The 7th edition of TNM for lung cancer: Implications for clinical care and research
|
Goldstraw, Peter
|
|
2012
|
77 |
S1 |
p. S3-
1 p.
|
artikel
|
| 89 |
Toxicity of molecular targeted agents in lung cancer. Do we need a new classification?
|
Jassem, Jacek
|
|
2012
|
77 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 90 |
Tumor-selective sensitization of NSCLC to TRAIL by Mdivi-1
|
Suzuki, Yoshihiro
|
|
2012
|
77 |
S1 |
p. S17-
1 p.
|
artikel
|
| 91 |
UK lung cancer survival: Where are we going wrong?
|
Wilson, Henrietta
|
|
2012
|
77 |
S1 |
p. S41-
1 p.
|
artikel
|
| 92 |
Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts)
|
Skřičková, Jana
|
|
2012
|
77 |
S1 |
p. S38-
1 p.
|
artikel
|
| 93 |
Volatile Organic Compounds (VOC) in exhaled breath in patients with lung cancer (LC)
|
Jareño, J.
|
|
2012
|
77 |
S1 |
p. S31-S32
2 p.
|
artikel
|
Tijdschrift beschrijving